News Release

ESMO Breast Cancer 2024: Event announcement

ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May

Meeting Announcement

European Society for Medical Oncology

Lugano, Switzerland, 8 May 2024ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented. Participants from all over the world are expected to come to Berlin to listen to renowned experts presenting key innovative areas – including new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications – and providing perspectives on how transformative new data can find a clear path to the clinic.  

The congress can be attended in person and online. 

The scientific programme is already available online. 


Programme highlights 

  • Novel data on safety of assisted reproductive techniques in patients with BRCA mutation. 

    • Related content: 266O 


  • Encouraging approaches to improve genitourinary symptoms and sexual health in breast cancer survivors. 


  • Promising new targets for antibody-drug conjugates (ADCs) within the precision medicine landscape. 

    • Related Content: 60P, Session on 16 May, 08:30 - 10:00 CEST 


  • New insights exploring patients’ understanding of biomarkers and biomarkers-based treatment decisions in early and metastatic breast cancer. 

    • Related content: 71P, Session on 15 May,16:45 - 18:15 CEST 


  • Findings on the growing application and benefits of artificial intelligence in breast cancer care. 

    • Related content: 65P, 66P, Session on 17 May, 08:30 - 10:00 CEST 


  • Enriching perspectives on hot topics and areas of unmet need: ctDNA in practice and the management of central nervous system metastases. 

    • Related content: Session on 16 May, 10:30 - 12:00 CEST;  Session on 17 May, 10:30 - 12:00 CEST 


  • Results of phase 3 studies in: 

    • Metastatic triple-negative breast cancer – Related content:180O 

    • Metastatic and advanced breast cancer – Related content: LBA2, 182MO, 183MO 

    • Early breast cancer – Related content: 113MO 


Keynote Lecture 

The results of 279 studies will be presented and published online as a supplement to ESMO Open. 


Press accreditation 

ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Tuesday, 14 May. Please be kindly informed that onsite press accreditation will not be possible. 


Third Parties Media registration 

Third Party Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through (Cc 


Further information 

ESMO Press Office 


Notes to editors 

Please make sure to use the official name of the meeting in your reports: ESMO Breast Cancer 2024 and the official congress hashtag #ESMOBreast24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube. 


About the European Society for Medical Oncology (ESMO) 

Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.    

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.